Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336721 | 0.84 | LMNA (0.42) | PDE7ASMN1; SMN2MAPTNPSR1KMT2A | |
| SCHEMBL3044512 | 0.77 | PDE7A (0.37) | PDE7ASMN1; SMN2MAPTNPSR1KMT2A | |
| SCHEMBL3838786 | 0.74 | PDE7A (0.35) | PDE7ASMN1; SMN2MAPTNPSR1KMT2A | |
| SCHEMBL3055047 | 0.74 | GPR35 (0.39) | PDE7ASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL28351783 | 0.74 | LMNA (0.46) | PDE7ASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL8095611 | 0.72 | PDE7A (1.00) | PDE7ASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL11554587 | 0.72 | SIRT1 (0.53) | SMN1; SMN2MAPTKMT2AMEN1KDM4E | |
| SCHEMBL28613090 | 0.71 | PDE7A (0.34) | PDE7ASMN1; SMN2 | |
| Silver SCHEMBL29146010 | 0.71 | ALOX15 (0.59) | PDE7ASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL11102967 | 0.70 | PDE7A (0.61) | PDE7ASMN1; SMN2MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129377-B2 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7041844-B2 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-05-09 | — | — | US | disclosed |
| US-20040248862-A1 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | TENNESSEE RESEARCH FOUNDATION, UNIVERSITY OF | 2004-12-09 | — | — | US | disclosed |
| US-20030232882-A1 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2003-12-18 | — | — | US | disclosed |
| US-6482861-B2 | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF AN ARYL AMIDE CONTAINING COMPOUND, WHICH BINDS IRREVERSIBLY TO THE ANDROGEN RECEPTOR OF THE PROSTATE CANCER PATIENT | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-20010012839-A1 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | MILLER DUANE D (US) | 2001-08-09 | — | — | US | disclosed |
| US-6071957-A | TREATING PROSTRATE CANCER BY ADMINISTERING EFFECTIVE AMOUNT OF ANTIANGROGEN COMPOUND WHICH BINDS IRREVERSIBLY TO ANDROGEN RECEPTOR | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232882-A1 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | AR, KLK3, NR5A1 | PDE7A 1647/4885SMN1; SMN2 4870/4885MAPT 3717/4885 |
| US-20010012839-A1 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | AR, KLK3, NR5A1 | PDE7A 1647/4885SMN1; SMN2 4870/4885MAPT 3717/4885 |
| US-20040248862-A1 | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer | AR, ESRRA, BRDT | PDE7A 1803/4885SMN1; SMN2 4869/4885MAPT 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.